BACKGROUND: In type 1 diabetes (T1D), closed-loop systems provide excellent overnight fasting blood glucose control by adjusting the insulin infusion rate based on corresponding changes in sensor glucose levels. In patients on multiple daily insulin (MDI) injections, such control in overnight glucose levels has not been possible due to the inability to alter the absorption rate of long-acting insulin after injection. In this study, we tested the hypothesis that increases/decreases of fasting glucose levels could be achieved by cooling/warming the skin around the injection site, which would result in lower/higher Glargine absorption rates from its subcutaneous depot. METHODS:Fourteen subjects with T1D (4 females; age 39.6 ± 16.7 years, HbA1c 7.8 ± 1.1%, BMI 25.4 ± 2.8 kg/m2) on MDI therapy underwent fasting pharmacokinetic and pharmacodynamic studies that started at ~8 am and lasted 240 min on 3 separate days in random order: a control day without warming or cooling of the injection site and two experimental days, one day with injection site warming and the other with cooling. RESULTS: Cooling the skin around the glargine injection site reduced insulin concentrations by >40% (P < .01 versus the warming study, P = .21 versus the control study), accompanied by a 55 mg/dL increase in serum glucose (P < .01 versus the control study). Conversely, skin warming prevented the fall in serum insulin (P = .2 versus the control study; P < .01 versus the cooling study), resulting in a 40 mg/dL reduction in serum glucose (P < .001 versus the cooling study, P = .11 versus the control study). CONCLUSIONS: This proof of concept study has shown that cooling and warming the skin around the injection site provides a means to decrease and increase the rate of absorption and action of insulin glargine from its subcutaneous depot.
RCT Entities:
BACKGROUND: In type 1 diabetes (T1D), closed-loop systems provide excellent overnight fasting blood glucose control by adjusting the insulin infusion rate based on corresponding changes in sensor glucose levels. In patients on multiple daily insulin (MDI) injections, such control in overnight glucose levels has not been possible due to the inability to alter the absorption rate of long-acting insulin after injection. In this study, we tested the hypothesis that increases/decreases of fasting glucose levels could be achieved by cooling/warming the skin around the injection site, which would result in lower/higher Glargine absorption rates from its subcutaneous depot. METHODS: Fourteen subjects with T1D (4 females; age 39.6 ± 16.7 years, HbA1c 7.8 ± 1.1%, BMI 25.4 ± 2.8 kg/m2) on MDI therapy underwent fasting pharmacokinetic and pharmacodynamic studies that started at ~8 am and lasted 240 min on 3 separate days in random order: a control day without warming or cooling of the injection site and two experimental days, one day with injection site warming and the other with cooling. RESULTS: Cooling the skin around the glargine injection site reduced insulin concentrations by >40% (P < .01 versus the warming study, P = .21 versus the control study), accompanied by a 55 mg/dL increase in serum glucose (P < .01 versus the control study). Conversely, skin warming prevented the fall in serum insulin (P = .2 versus the control study; P < .01 versus the cooling study), resulting in a 40 mg/dL reduction in serum glucose (P < .001 versus the cooling study, P = .11 versus the control study). CONCLUSIONS: This proof of concept study has shown that cooling and warming the skin around the injection site provides a means to decrease and increase the rate of absorption and action of insulinglargine from its subcutaneous depot.
Authors: Eda Cengiz; Stuart A Weinzimer; Jennifer L Sherr; Eileen M Tichy; Lori Carria; Darryll Cappiello; Amy Steffen; William V Tamborlane Journal: Diabetes Technol Ther Date: 2013-12-24 Impact factor: 6.118
Authors: Anne Peters; Michelle A Van Name; Brian Larsen Thorsted; Johanne Spanggaard Piltoft; William V Tamborlane Journal: Endocr Pract Date: 2017-07-13 Impact factor: 3.443
Authors: Michelle A Van Name; Marisa E Hilliard; Claire T Boyle; Kellee M Miller; Daniel J DeSalvo; Barbara J Anderson; Lori M Laffel; Stephanie E Woerner; Linda A DiMeglio; William V Tamborlane Journal: Pediatr Diabetes Date: 2017-04-21 Impact factor: 4.866
Authors: Richard M Bergenstal; Satish Garg; Stuart A Weinzimer; Bruce A Buckingham; Bruce W Bode; William V Tamborlane; Francine R Kaufman Journal: JAMA Date: 2016-10-04 Impact factor: 56.272
Authors: Eva Tsalikian; Nelly Mauras; Roy W Beck; William V Tamborlane; Kathleen F Janz; H Peter Chase; Tim Wysocki; Stuart A Weinzimer; Bruce A Buckingham; Craig Kollman; Dongyuan Xing; Katrina J Ruedy Journal: J Pediatr Date: 2005-10 Impact factor: 4.406
Authors: T W Jones; P Porter; R S Sherwin; E A Davis; P O'Leary; F Frazer; G Byrne; S Stick; W V Tamborlane Journal: N Engl J Med Date: 1998-06-04 Impact factor: 91.245
Authors: Jason P Pitt; Olivia M McCarthy; Thomas Hoeg-Jensen; Benjamin M Wellman; Richard M Bracken Journal: Front Endocrinol (Lausanne) Date: 2020-10-21 Impact factor: 5.555